Skip NavigationSkip to Content

The interaction of spongistatin 1 with tubulin

  1. Author:
    Bai,Ruoli
    Smith, Amos B
    Pettit, George R
    Hamel,Ernest
  2. Author Address

    Molecular Pharmacology Branch (RB, EH), Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA., Department of Chemistry, University of Pennsylvania, Philadelphia, PA, 19104, ABS, USA., Laboratory for Discovery of Anti-Cancer and Anti-Infective Drugs, School of Molecular Sciences, Arizona State University, Tempe, AZ 85287, GRP, USA., Molecular Pharmacology Branch (RB, EH), Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA. Electronic address: hamele@mail.nih.gov.,
    1. Year: 2022
    2. Date: May 17
    3. Epub Date: 2022 05 17
  1. Journal: Archives of Biochemistry and Biophysics
    1. Pages: 109296
  2. Type of Article: Article
  3. Article Number: 109296
  1. Abstract:

    A tritiated derivative of the sponge-derived natural product spongistatin 1 was prepared, and its interactions with tubulin were examined. [3H]Spongistatin 1 was found to bind rapidly to tubulin at a single site (the low specific activity of the [3H]spongistatin 1, 0.75?Ci/mmol, prevented our defining an association rate), and the inability of spongistatin 1 to cause an aberrant assembly reaction was confirmed. Spongistatin 1 bound to tubulin very tightly, and we could detect no significant dissociation reaction from tubulin. The tubulin-[3H]spongistatin 1 complex did dissociate in 8?M urea, so there was no evidence for covalent bond formation. Apparent KD values were obtained by Scatchard analysis of binding data and by Hummel-Dreyer chromatography (3.5 and 1.1?µM, respectively). The effects of a large cohort of vinca domain drugs on the binding of [3H]spongistatin 1 to tubulin were evaluated. Compounds that did not cause aberrant assembly reactions (halichondrin B, eribulin, maytansine, and rhizoxin) caused little inhibition of [3H]spongistatin 1 binding. Little inhibition also occurred with the peptides dolastatin 15, its active pentapeptide derivative, vitilevuamide, or diazonamide A, nor with the vinca alkaloid vinblastine. Strong inhibition was observed with dolastatin 10, hemiasterlin, and cryptophycin 1, all of which cause aberrant assembly reactions that might actually mask the spongistatin 1 binding site. Spongistatin 5 was found to be a competitive inhibitor of [3H]spongistatin 1 binding, with an apparent Ki of 2.2?µM. We propose that the strong picomolar cytotoxicity of spongistatin 1 probably derives from its extremely tight binding to tubulin. Copyright © 2022. Published by Elsevier Inc.

    See More

External Sources

  1. DOI: 10.1016/j.abb.2022.109296
  2. PMID: 35594923
  3. PII : S0003-9861(22)00180-1

Library Notes

  1. Fiscal Year: FY2021-2022
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel